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| INTRODUC TI ON
A basic tenet of clinical pharmacology is that only unbound (free) drug molecules can interact with target receptors that are present on cell membrane or with enzymes that are located inside the cell, and therefore the intensity and duration of drug action are mediated via the time course of unbound drug concentrations at the site of action. With few exceptions, most drug target receptors or enzymes are located outside of the blood circulation in the target tissues. Although unbound drug concentrations in blood can be readily measured, direct assessment of unbound drug concentration at the action site in target tissues is seldom possible due to inaccessibility of the action sites.
For this reason, the unbound drug concentration in blood (plasma)
is often used to establish pharmacokinetics-pharmacodynamics (PK-PD) relationship by applying the so-called free drug hypothesis. The hypothesis assumes that the unbound drug concentration in blood is the same as that in the site of action at steady state. 1, 2 From literature, the free drug hypothesis appears valid for many drugs. The unbound concentrations of drugs in peripheral tissues and brain are quantitatively similar to those in plasma. [3] [4] [5] [6] [7] However, the hypothesis is not applicable for some drugs. For examples, the unbound concentrations of morphine, gabapentin, and atenolol in the brain are significantly lower than those in plasma. [8] [9] [10] [11] Over the years, with the progress of molecular biology, it has become evident that efflux drug transporters (such as P-gp, BCRP, and MRPs) play an important role not only in drug excretion but also in tissue distribution (drug transport), particularly for brain uptake. [12] [13] [14] [15] For drugs that are substrates of efflux transporters, at steady state, the unbound drug concentrations in tissues are expected to be lower than unbound drug concentrations in plasma, when efflux transporters are involved in tissue distribution. Based on the involvement of efflux transporters, drugs can generally be categorized into two classes: drugs that are not substrates of efflux transporters (Class I) and drugs that are substrates of efflux transporters (Class II). It is expected that the free drug hypothesis will not be valid for drugs that are substrates of efflux transporters. Conceivably, the free drug hypothesis is also not applicable for drugs that are substrates of influx transporters. Unbound drug concentration in tissues is expected to be higher for influx transporter drugs than that in plasma.
The brain can serve as a suitable target organ to test the free drug hypothesis by comparing unbound drug concentrations in the brain and blood. As part of its protective mechanism, various drug efflux transporters are highly expressed at the BBB. 16, 17 Many compounds that enter the brain are efficiently removed by efflux drug transporters. P-glycoprotein (P-gp) is the best-known efflux transporter at the BBB, but others, like breast cancer-resistance protein (BCRP) and multidrug-resistance-associated proteins (MRPs), may also contribute to the removal process. Efflux transporters use the hydrolysis of ATP to transport their substrates up against their concentration gradient. 18, 19 Although the free drug hypothesis has been explicitly used to explain the pharmacokinetics and pharmacodynamics (PK/PD) relationship for several decades, it has not been directly and systemically proven. In most studies that intended to validate the hypothesis, comparison of unbound drug concentrations in the target tissues (such as brain) and in plasma was conducted by indirect measurement of unbound concentrations. In other words, the blood and brain unbound concentrations were indirectly determined by in vitro plasma and brain binding data (unbound fractions), respectively.
For example, Summerfiel et al conducted a study to compare plasma unbound drug concentrations with brain unbound drug concentrations for more than 50 compounds. 20 In this study, the plasma unbound concentrations were calculated from the product of the plasma unbound fraction and plasma total concentration, while the brain free concentrations were calculated from the product of the brain unbound fraction and brain total concentration. Similar approaches have also been adapted by other investigators. 21, 22 However, drug binding in brain homogenates may not accurately reflect the binding in intact brain in vivo because tissue homogenates do not take into account the fact that drug binding may differ between interstitial fluid, cells, and subcellular organelles. In a study by Liu et al, 22 unbound drug concentrations of nine compounds measured by microdialysis (C m,brain ) were compared to the unbound drug concentrations (C u,brain ) measured by employing unbound fraction in diluted brain homogenates. More than 2-fold differences between the C m,brain and C u,brain were observed in five of the nine test compounds (56%).
The objective of our study is to determine whether the free drug hypothesis is universally applicable to all drugs. Since microdialysis provides a reliable and direct measurement of unbound drug concentrations in the brain and blood in vivo, unbound drug concentrations in brain and blood are measured directly and simultaneously in rats by microdialysis, rather than indirectly calculated from plasma and brain binding.
| MATERIAL S AND ME THODS

| Chemicals
In all, 18 compounds with different physiochemical properties were selected for this study. Antipyrine, ganciclovir, ofloxacin, 4-aminoantipyrine, lamotrigine, theophylline, citalopram, digoxin, quinidine, pemetrexed, atenolol, carbamazepine, propranolol, and diltiazem were purchased from MedChemExpress (Monmouth Junction).
Acetaminophen was purchased from Sigma-Aldrich. Fexofenadine and sumatriptan were purchased from Tokyo Chemical Industry.
Cimetidine was purchased from National Institute for the Control of Pharmaceutical and Biological Products. All the other chemicals were of the HPLC grade or better.
| Animals
Male Sprague-Dawley rats (8-10 weeks, 250-350 g) were purchased from Sibeifu Biotechnology Co., Ltd. The animals were acclimatized to the laboratory environment for at least 1 week before the study and were housed in a 12 hour light/12 hour dark cycle environment with free access to food and water. All studies were approved by Pharmaron's Institutional Animal Care and Use Committee (IACUC).
| Madin-Darby Canine Kidney and Caco-2 cell assays
Bidirectional permeability of test compounds was evaluated using Madin-Darby Canine Kidney (MDCK) II cell line transfected with or without human MDR1 (MDR1-MDCK, Netherlands Cancer Institute), and Caco-2 cell line (American Type Culture Collection).
MDCK, MDR1-MDCK, and Caco-2 cells were cultured at 37°C, 5% The apparent permeability (P app ) was calculated as follows:
where V A , Area, and time represent the volume in the acceptor well 
| Rat pharmacokinetic studies
Pharmacokinetic studies of test compounds were conducted in male Sprague-Dawley rats (n = 3). Each of the 18 compounds was administered intravenously to separate groups of animals via tail vein injection. Lamotrigine, acetaminophen, 4-aminoantipyrine, atenolol, quinidine, and fexofenadine were prepared in "10% hydroxypropyl-β-cyclodextrin in water." Digoxin, citalopram, carbamazepine, sumatriptan, and diltiazem were prepared in "DMSO/10% hydroxypropyl-β-cyclodextrin in water (v/v, 5/95)." The rest compounds were prepared in Saline. Blood samples were collected via jugular vein at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post-dose and placed into EDTA-K 2 coated tubes. Blood was then centrifuged at 4000g for 5 minutes to obtain plasma. Samples were stored at −75 ± 15°C before analysis. protocol. 23 The cannula and dummy probe were secured to skull with screws and dental cement. Animals were acclimated to laboratory environment for 3-4 days prior to microdialysis study. At 18 hours before dosing, animals were placed into an individual system of freely moving environment, and then blood microdialysis probe (CMA/20, 10 mm, CMA) was implanted into jugular vein while the pre-implanted dummy probe in brain was replaced by brain microdialysis probe (CMA/12, 4 mm, CMA). The two probes were perfused with blank acid citrate dextrose (ACD; 3.5 mmol/L citric acid, 7.5 mmol/L sodium citrate, 13.6 mmmol/L dextrose) and artificial cerebrospinal fluid (aCSF; 147 mmmol/L NaCl, Table 1 . Brain and blood microdialysis dialysates were collected at 0.5 hours intervals up to 6 hours post-dose. At 6 hours, animals were subsequently euthanized, then cerebrospinal fluids (CSF) and brain samples were collected. All samples were stored at −75 ± 15°C before analysis.
| Rat brain and blood microdialysis studies
| Rat microdialysis studies at additional two different brain positions
Unbound brain concentrations of acetaminophen and antipyrine were measured by microdialysis method at additional two different the procedure in previous microdialysis study described above.
Dose and formulation remained same as they were in the previous microdialysis study. Brain microdialysis dialysates were collected at 0.5 hours intervals up to 6 hours post-dose. All samples were stored at −75 ± 15°C before analysis.
| In vivo recovery studies
The recovery of compounds in brain and blood microdialysis probes was determined by an in vivo retrodialysis method. Brain and blood probes were implanted into animals following the procedure in previous microdialysis study. 24 300 ng/mL of test compounds (250 ng/ mL for acetaminophen) in ACD and aCSF were constantly perfused into blood and brain probes for 5 hours, and dialysates were collected at 0.5 hours intervals from 2 to 5 hours Recovery can be calculated by following equation:
where C in is the concentration in perfusates while C out is the average concentration of dialysates collected from 2 to 5 hours Samples were stored at −75 ± 15°C before analysis. The recovery data of the microdialysis probes is listed in Table 1 . 10 μL of dialysates and CSF samples were mixed with 100 μL of acetonitrile containing internal standard. Supernatants were diluted with appropriate volumes of water before analysis on HPLC/MS/MS.
| Sample analysis
| Data analysis
Pharmacokinetic parameters were calculated with WinNolin 8.0 (Pharsight Corporation) by employing a non-compartmental analysis. Graphs and statistical analysis were performed in Prism 7.0 (Graphpad).
ANOVA was used to determine the statistical difference of steady-state unbound concentrations in blood, brain, and CSF. The
TA B L E 1 Loading doses, infusion rates, formulations, and microdialysis probe recoveries used for the 18 compounds in rat microdialysis study (n = 3; mean ± SD)
Compound name
Loading dose (mg/kg) statistical difference of the steady-state unbound brain concentrations measured by microdialysis at three different positions was also analyzed by ANOVA. A correlation analysis was performed to evaluate the relationship of the steady-state unbound concentration between brain and blood; and between brain and CSF.
IV Infusion dose (mg/kg/h) Formulation
Probe recovery (blood) (%)
Probe recovery (brain) (%)
Acetaminophen
| RE SULTS
In all, 18 structurally diverse compounds with different physicochemical properties were selected for the rat microdialysis study.
Pharmacokinetic studies were conducted to obtain kinetic param- [25] [26] [27] On the other hand, the mean values of plasma CL were 1.48 and 1.58 mL/min/kg, respectively, for lamotrigine and theophylline in rats in this study (Table 2) , while the reported mean values for the corresponding compounds were 0.83 and 2.39 mL/min/kg. 28, 29 Kinetically, approximately five half-lives (T 1/2 ) are needed to achieve the target steady-state concentration (C ss ) following a constant rate of intravenous infusion. One can use a loading dose to quickly achieve the desired steady-state drug concentration. The loading dose and infusion rate of each drug can be calculated by the following Equations (4) and (5), respectively, using the kinetic parameters and the pre-determined desired C ss .
Loading doses and infusion rates for the test compounds are listed in Table 1 . Table 3 . In addition, the P app(B-A) and P app(A-B) and ER values of the test compounds measured by Caco-2 monolayers are presented in Table 4 .
The cell membrane permeability (P app(B-A) and P app(A-B) ) of the 18 compounds measured by the parent MDCK cells is listed in (Table 4 ). It is of interest to note that the ER values of fexofenadine and digoxin measured by Caco-2 cell assay were much greater than those by MDR1-MDCK cell assay. It is well known that Caco-2 cells express many major efflux transporters, including P-gp, BCRP, and MRPs. [31] [32] [33] These results suggest that fexofenadine and digoxin are not only substrates of P-gp but also substrates of other efflux transporters, possibly BCRP and/or MRPs.
Digoxin is a well-known substrate of rat and human P-gps and is often used as a probe in in vitro and in vivo drug-drug interaction involving P-gp. 34, 35 In this study, the ER values of digoxin were estimated to be 17.1 and 48.2, respectively, when measured by MDR1-MDCK and Caco-2 assays (Tables 3 and 4 ). The ER measured in Caco-2 cell assay was markedly greater than in MDR1-MDCK cell assay. These results suggest that digoxin efflux involves not only P-gp but also other efflux transporters, since
Caco-2 cells express many efflux transporters. Similar observations were reported by Wang et al 36 The ER value of digoxin was markedly higher in Caco-2 cell assay (ER = 120) than in MDR1-
MDCK cell assay (ER = 17).
Similarly, fexofenadine is also known to be a P-gp substrate. 37 In this study, the ER values of fexofenadine were estimated to be 2.89 and 21.6, respectively, for MDR1-MDCK and Caco-2 cell assays (Tables 3 and 4 ). These results suggest that fexofenadine also involves other efflux transporters in addition to P-gp. The notion that fexofenadine efflux involves multiple efflux transporters is supported by other investigators. A study was conducted to compare the biliary excretion of fexofenadine in wild-type and Mrp2knockout mice. 38 The authors concluded that more than 50% of biliary excretion of fexofenadine was attributed to Mrp2, with P-gp and Bcrp playing a minor role in mice.
Quinidine is also known to be P-gp substrates. 39 In this study,
the ER values of quinidine were estimated to be 6.24 and 9.2, respectively, for MDR1-MDCK and Caco-2 cell assays (Tables 3 and 4 ).
These results suggest that quinidine efflux may only involve P-gp. It is interesting to note that quinidine poorly penetrated the brain even with a good permeability (19.1 × 10 −6 cm/sec; Table 3 ). Good permeability of quinidine has also been reported by other investigators. In a study with MDCK-MDR1-NKI cell lines, the permeability was about 60 × 10 −6 cm/sec for quinidine. 40 In another study, the permeability was about 14 × 10 −6 cm/sec for quinidine, when Caco-2 cells were used. 41 It is interesting to note that quinidine has a reasonably good permeability (19.1 × 10 −6 cm/sec), even though it is a good P-gp substrate (Table 3 ). There are many good P-gp substrates that show good permeability. For example, indinavir and neflinivir are excellent P-gp substrates with very good permeability. The ER values were 25 and 22, respectively, for indinavir and neflinivir, respectively, while the corresponding values of permeability were 85 × 10 −6 cm/sec and 197 × 10 −6 cm/sec. 42 The ER values of sumatriptan were 2.25 and 2.12, respectively, for MDR1-MDCK and Caco-2 cell assays (Tables 3 and 4 ). These results suggest that sumatriptan is a P-gp substrate. The notion that sumatriptan is a P-gp substrate is supported by a rat study conducted by Summerfield et al 20 In their rat study, the ER value of sumatriptan obtained from MDR1-MDCK assay was reported to be 2.9, and the steady-state unbound concentrations in the brain was about 20-fold lower than that in plasma.
Although the ER values of ganciclovir, ofloxacin, and cimetidine were less than 2.0 in MDR1-MDCK cell assay, the ER values were greater than 2.0 in Caco-2 assay. The ER was 1.69, 1.13, and 1.68, respectively, for ganciclovir, ofloxacin, and cimetidine in MDR1-MDCK cell assay, while the corresponding ER values were 2.61, 2.99, and 9.2 in Caco-2 assay (Tables 3 and 4 ). These results suggest that ganciclovir, ofloxacin, and cimetidine are substrates for other efflux transporters (such as BCRP and MRPs), but not P-gp.
In this study, treatment of Caco-2 cells with novobiocin resulted in a marked decrease in the ER of cimetidine, from 9.20 to 3.29 (in supplemental data). Novobiocin is known to be potent BCRP inhibitor. 43 These results suggest that cimetidine efflux may involve efflux transporter BCRP. The notion that ofloxacin is not a P-gp substrate is supported by other investigators. In an in vitro study, neither P-gp nor BCRP affected the efflux transport of ofloxacin.
In contrast, it revealed pronounced MRPs involvement in the transfer of ofloxacin. 44 The ER values of ganciclovir were less than 2.0 in MDR1-MDCK assay, and equal to 2.61 in Caco-2 assay (Tables 3 and   4 ). These results suggest that the compound is a substrate of efflux transporters, but not P-gp. In vitro studies revealed that ganciclovir is a substrate of MRP4. 45, 46 Although the ER values of atenolol and pemetrexed were less than 2.0 in both MDR1-MDCK and Caco-2 cell assays, these two compounds showed poor membrane permeability, suggesting that efflux transporters may be involved in their membrane transport.
Based on the membrane permeability and ER value that were The unbound concentrations of the 18 compounds in blood and in brain interstitial fluids (ISF) following constant intravenous infusion were simultaneously monitored via in vivo microdialysis technique.
The unbound concentration-time profiles of Class I compounds in the brain and blood are presented in Figure 1 , while unbound concentration-time profiles of Class II compounds are shown in Figure 2 .
As shown in Figures 1 and 2 , the unbound drug concentrations of all compounds in blood and brain remained relatively constant from about 1-2 hours up to 6 hours after the commencement of infusion.
These results suggest that a steady state was reached rapidly for all Class I and Class II compounds.
As shown in Table 5 , the steady-state unbound drug concentrations in blood (C m,blood ) were quantitatively similar to that in the brain (C m,brain ) for the Class I compounds. In contrast, the steady-state unbound drug concentrations in the brain were statistically much lower than that in blood for Class II compounds ( Table 6 ). The differences in steady-state unbound drug concentrations between the brain and blood ranged from 3.9-fold for quinidine to 86-fold for pemetrexed, respectively.
For comparison purposes, steady-state unbound drug concen- sacrificed at the end of constant infusion (6 hours), and CSF samples were collected. The unbound drug concentrations in CSF (C csf ) were quantitatively similar to the steady-state unbound drug concentrations measured by microdialysis (C m,brain ) for most compounds of Class I, with the exception of 4-aminoantipyrine, lamotrigine, and carbamazepine ( Table 5 ). The C csf of 4-aminoantipyrine was somewhat lower than C m,brain , while the C csf values were slightly higher than the C m,brain for lamotrigine and carbamazepine ( Table 5 ).
For Class II compounds, the C csf values were generally lower than C m,brain with the exception of ofloxacin, pemetrexed, and digoxin ( Table 6 ).
As shown in Figure 3 , there is a good correlation between the steady-state C m,brain and C m,blood for Class I compounds with a correlation coefficient (R 2 ) of .937. Similarly, a good correlation between the steady-state C m,brain and C csf of Class I compounds was observed with a correlation coefficient of 0.862. These results suggest that there is a fairly strong relationship between the steady-state C m,brain and C m,blood as well as between the steady-state C m,brain and C csf for compounds with good permeability that are not substrates of efflux transporters.
In contrast, the correlation between the steady-state C m,brain and C csf was poor for Class II compounds. The correlation coefficient was only 0.147 ( Figure 3 ). However, it is a bit surprising to see that there was a reasonably good correlation between the steady-state C m,brain and C m,blood for Class II compounds with a correlation coefficient of 0.803 (Figure 3 ). It should be noted that the steady-state C m,brain were much lower than the steady-state C m,blood for Class II compounds by a factor of 4-86 fold. Therefore, the "reasonably good" correlation between the steady-state C m,brain and C m,blood for Class II compounds is statistically less meaningful.
A study was conducted to ensure that unbound drug concentrations are evenly distributed within the brain. For this purpose, Table 7 , the steady-state unbound concentrations of acetaminophen and antipyrine were quantitatively similar among the three different sites of the rat brain. An ANOVA test suggests that there was no statistical difference in the steady-state unbound drug concentrations among the three sites. These results strongly suggest that unbound drug molecules are evenly distributed within the brain. TA B L E 5 Steady-state unbound drug concentrations in blood, brain, and CSF of class I compounds with good membrane permeability that are not efflux transporter substrates (n = 3-4; mean ± SD)
The authors have shown that the unbound drug concentrations of antipyrine, midazolam, and lamotrigine at the cortex were quantitatively similar to those at the hippocampus in rats. TA B L E 6 Steady-state unbound drug concentrations in blood, brain, and CSF of class II compounds that are efflux transporter substrates (n = 3-4; mean ± SD)
| D ISCUSS I ON
F I G U R E 3
The correlation between unbound brain concentration (C m,brain ) and unbound blood concentration (C m,blood , A and B), and unbound CSF concentration (C csf , C and D) at steady state in rats after 6 hours infusion (mean ± SD, n = 3-4)
further confirmed that P-gp of rodents and humans share similar binding modes. In another study, the permeability and efflux 51 Inhibitor studies showed that digoxin efflux in intestinal tissues was mainly mediated by P-glycoprotein.
Together, these results suggest that functional activities of human efflux transporters are qualitatively and quantitatively similar to those of rat efflux transporters.
However, significant species differences in P-glycoprotein transport activity exist between humans and animals. 14, 52 In a drug dis- As shown in Figure 1 , the unbound drug concentrations of all Class I compounds in blood and brain remained relatively constant from about 1-2 hours up to 6 hours after the commencement of infusion, suggesting a steady state was reached. The steady-state blood unbound drug concentrations (C m,blood ) measured by microdialysis were quantitatively very similar to those in the brain (C m,brain ) measured by microdialysis. There were no statistical differences between the C m,brain and C m,blood for all compounds (Table 5 ). These results strongly suggest that the free drug hypothesis is applicable to the Class I compounds that have good permeability and are not substrates of efflux transporters. If the free drug hypothesis is applicable to the Class I compounds, the unbound drug concentrations in CSF (C csf ) are expected to be quantitatively similar to that in the brain (C m,brain ). It is unexpected that the C csf of 4-aminoantipyrine, lamotrigine, and carbamazepine was statistically different from C m,brain . As shown in Table 5 , the C csf of 4-aminoantipyrine was somewhat lower than C m,brain by about 25%, while the C csf values were slightly higher than the C m,brain for lamotrigine (45%) and carbamazepine (25%). The reason for the significant differences between C csf and C m,brain for the three compounds is not clear.
The unbound concentrations of all Class II compounds in blood and brain also remained relatively constant, and a steady state was reached around 1-2 hours after the commencement of infusion ( Figure 2 ). However, the unbound concentrations in the brain were markedly lower than blood for all the compounds. The differences in the steady-state unbound drug concentrations between the brain and blood ranged from 3.9-fold for quinidine to 86-fold for pemetrexed, respectively ( Table 6 ). It is important to point out that steady-state unbound concentrations of drugs in all tissues (organs) should be equal, unless an organ has a clearance process or efflux transport process. 54 It is generally accepted that the brain is not an organ of drug metabolism. Therefore, the marked differences in unbound concentrations between the brain and blood for Class II compounds strongly suggest that these compounds are substrates of efflux transporters. Tables 3 and 4 , all Class II compounds are substrates of efflux transporters except atenolol and pemetrexed.
As shown in
The ER values of atenolol and pemetrexed were 0.416 and 0.623, respectively, for MDR1-MDCK assay, while the corresponding values were 1.49 and 1.81 for Caco-2 assay. These results suggest that atenolol and pemetrexed are not substrates of efflux transporters (P-gp, BCRP, and MRPs). Kinetically, the steady-state unbound concentrations of a drug in the brain and blood should be equal, unless there is an involvement of carrier-mediated efflux transport of the drug at BBB. 54 If atenolol and pemetrexed are not substrates of efflux transporters, it is expected that the unbound drug concentrations in the brain are quantitatively similar to that in blood. Unexpectedly, the steady-state unbound concentrations of atenolol and pemetrexed in the brain were substantially lower than that in blood ( Figure 2 and Table 6 ). The marked differences in steady-state unbound concentrations between the brain and blood strongly suggest that atenolol and pemetrexed are substrates of some unknown efflux transporters.
In vitro and in vivo studies have revealed that pemetrexed is a good substrate of BCRP and MRPs which are expressed in the BBB acting as efflux transporters. 55 However, conflicting results have been reported by other investigators. Using brain efflux index method, efflux of pemetrexed from brain to blood after intracerebral microinjection was studied in wild-type, Bcrp1 −/− , and Mrp2 −/− mice. 56 TA B L E 7 Steady-state unbound drug concentrations at three different brain positions with microdialysis method. (n = 3; mean ± SD)
Compound name
Pemetrexed was eliminated rapidly from the brain to blood circulation even in Bcrp1 −/− and Mrp2 −/− mice, when the compound was injected into the rat brain. Results from this study indicated that Mrp2 and Bcrp1 did not play an important role in the brain efflux of pemetrexed. Instead, the authors suggested that the involvement of organic anion transporters in the efflux of pemetrexed from the brain, with organic anion transporter 3 (Oat3) being a possibility. The identity of efflux transporters involved in brain efflux of pemetrexed is still unknown.
Atenolol is a hydrophilic compound with low membrane permeability. The steady-state ratio of unbound atenolol concentrations in brain to that in blood (ie, K p,uu,brain ) was about 0.12 in this study ( Table 6 ). Similar observations were also reported by other investigators. In a rat study using microdialysis, the K p,uu,brain of S-atenolol was reported to be about 0.04 by Chen et al 8 Results from our study and other investigators strongly suggest the possibility of an involvement of transporter-mediated efflux transport from the brain. However, the identity of the efflux transporter(s) is still unknown.
In conclusion, the free drug hypothesis is not universally applicable for all drugs, but only applicable for drugs with good permeability that are not substrates of efflux transporters. If the free drug hypothesis is applicable, the unbound drug concentrations in blood (plasma) at steady state can be used as a reliable surrogate for assessing the unbound drug concentrations at the site of action. It is evident that drugs with poor membrane permeability that are substrates of efflux transporters will not follow the free drug hypothesis. For drugs that are substrates of efflux transporters, the unbound drug concentrations in the brain are expected to be significantly lower than that in blood (plasma). An important lesson learned from this study is that in vitro transport study using transporter-transfected cell lines (such as MDR1-MDCK and/or Caco-2 cells) may sometimes fail to identify substrates of efflux transporters. Supplemental kinetic study in rodents may facilitate accurate identification of efflux transporters. Recently, it has been reported that the unbound concentrations of several drugs in the brain were greater than in plasma, suggesting the involvement of active influx transporters in brain uptake. 20, 57 Conceivably, drugs that are substrates of influx transporters are also not expected to follow the free drug hypothesis. The involvement of influx transporters in the brain uptake of drugs is currently an important research topic in our laboratory.
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